The p53 tumor suppressor regulates transcription of target genes. We have previously analysed the p53-dependent proteome and identified novel protein targets. Here we have examined p53-dependent phosphorylation using two-dimensional gel electrophoresis and staining with the fluorescent phosphoprotein dye Pro-Q Diamond. We report that p53 induces phosphorylation of a subset of proteins including Nm23, DJ-1, ANXA1 and PrxII. Our identification of p53-dependent phosphorylation of specific target proteins reveals new aspects of the p53-dependent cellular response and suggests that such posttranslational modifications may contribute to p53-mediated tumor suppression.
The tumor suppressor p53 executes its function mainly by transcriptional regulation of a set of target genes. Cellular stress conditions such as oncogenic signaling, DNA damage and hypoxia activate p53 that curbs cellcycle progression, allows DNA repair and/or induces programmed cell death. p53 is phosphorylated at multiple sites in its N-and C-terminal regions upon cellular stress, resulting in p53 stabilization and activation of DNA binding (for a review see Vousden and Lu, 2002) . In addition, activated p53 may carry out transcription-independent functions (Mihara et al., 2003) . Other modifications that are important for p53 function include ubiquitination, acetylation, methylation and sumoylation (Lavin and Gueven, 2006) . p53-regulated targets are involved in different cellular processes including DNA repair, differentiation, and cell-cycle arrest and apoptosis (Ryan et al., 2001) . Clearly, identification of new p53 targets is important to achieve a better understanding of the p53 tumor suppressor pathway. We have recently identified a series of novel p53 targets by protein-expression profiling (Rahman-Roblick et al., 2007) . It is conceivable that p53 regulates targets at the posttranslational level, for example by affecting posttranslational modifications such as phosphorylation via transcriptional activation of kinases or other mechanisms. In this study we sought to identify proteins that are posttranslationally modified by phosphorylation upon activation of wild-type p53 using the fluorescent phosphoprotein dye Pro-Q Diamond (Pro-QD) and 2DE-based polypeptide separation and mass spectrometry.
We first confirmed that treatment with the DNAdamaging agent mitomycin C (MMC) induced p53 in HCT116 wtp53
þ / þ cells. Upregulation of p53 targets p21 and MDM2 was verified by western blot analysis ( Figure 1a) . We also observed phosphorylation of p53 at Ser15, Ser20 and Ser392. Immunostaining showed upregulation of total p53 levels and phosphorylation at Ser15 and Ser37 after 16 h of MMC treatment (Figure 1b) . Assessment of apoptosis by fluorescenceactivated cell sorting (FACS) analysis of caspase activity showed much higher fraction of apoptotic cells in p53 þ / þ cells as compared to p53 À/À cells ( Figure 1c ). Total protein from HCT116 wtp53 þ / þ and corresponding p53 À/À cells treated with MMC for 0 and 16 h was separated by 2DE and stained for phosphoproteins using Pro-QD staining solution. We detected 3029 protein spots by Sypro Ruby (SR) staining in the two match sets (pH ranges 4.7-5.9 and 5.5-6.7). A total of 279 proteins showed changes in phosphorylation in MMC-treated wild-type p53 and/or p53 null cells. Forty-four of these protein spots were detected exclusively in the p53 þ / þ cells upon p53 activation. For protein identification, the gels were re-stained with SR staining solution and the interesting spots were excised and identified by mass spectrometry. Identity of 21 proteins phosphorylated in p53 þ / þ cells was obtained and is shown in Table 1 . Interestingly, 16 proteins were dephosphorylated upon MMC treatment in a p53-dependent manner (data not shown).
A Pro-QD-stained 2DE gel of HCT116 wtp53 þ / þ and p53 À/À cells after 16 h of MMC treatment is shown in Figure 2 . Phosphorylation of Annexin I (ANXA1) was detected only in the p53 þ / þ cells upon MMC treatment (Figure 2a) Figure 2b , ANXA1 was upregulated as well as phosphorylated in a p53-dependent manner, consistent with our previous results (Rahman-Roblick et al., 2007) .
Proteins that show p53-dependent phosphorylation in our analysis can be divided into two groups. The first group of proteins show altered total expression level, either enhanced or decreased, as well as changes in phosphorylation status. Proteins in the second group are only modified by phosphorylation without any detectable changes in total expression levels. The metastasisinhibitor protein Nm23 and ANXA1 belong to the first category. Nm23 is upregulated as shown by SR staining and phosphorylated in the HCT116 p53 þ / þ cells after MMC treatment (Figure 3a ). In contrast, we detected phosphorylation of the DJ-1 protein in MMC-treated HCT116 wtp53
þ / þ cells, but its total levels did not change ( Figure 3b ). These results indicate that p53 can not only transactivate specific genes and induce protein expression but also trigger posttranslational modification of a subset of proteins.
p53-dependent phosphorylation of ANXA1 and DJ-1 was also analysed by immunoprecipitation using an anti-phosphoserine/threonine/tyrosine antibody (antipSTT), followed by western blot analysis. We confirmed p53-dependent phosphorylation of ANXA1 and DJ-1 ( Supplementary Figures 4a and b) . We observed p53 phosphorylation as well (Supplementary Figure 4c) . To verify that phosphorylation of ANXA1 and DJ-1 was a direct effect of p53 induction and not a consequence of DNA damage per se, we performed immunoprecipitation with the anti-pSTT antibody following siRNA knockdown of p53 in MMC-treated p53 þ / þ cells. We detected phosphorylated ANXA1 and DJ-1 in the cells treated with control siRNA (siCtrl) but not in cells treated with p53 siRNA, confirming that phosphorylation of these proteins was indeed p53 dependent ( Supplementary Figures 5a and b) . We also confirmed inhibition of p53 induction and absence of upregulation of the p53 target MDM2 in the p53-siRNA-treated cells (Supplementary Figure 5c) .
To investigate whether p53-induced phosphorylation is dependent on transcription (p53 dependent or transcription in general), we blocked transcription by þ / þ and p53 À/À colon carcinoma cells (provided by Bert Vogelstein, Johns Hopkins Oncology Center, Baltimore, MD, USA) were grown in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal bovine serum, glutamin and gentamycin in 5% CO 2 at 37 1C. HCT116 cells were grown with or without 10 mg/ml mitomycin C to activate endogenous p53 (Sigma, St Louis, MI, USA). Western blotting was performed according to standard procedure using the following primary antibodies: mouse monoclonal anti-p53 (DO-1, Eurogenetics, Tessenderlo, Belgium), mouse monoclonal anti-MDM2 (2A10, provided by Sonia Lain, University of Dundee), mouse monoclonal anti-p21 (BD Pharmingen, San Diego, CA, USA), mouse monoclonal anti-b-actin (Sigma, St Louis, MI, USA). For detection of phosphorylation of p53, rabbit polyclonal anti-p53 Ser15, Ser20 and Ser392 (Cell Signaling Technology, Danvers, MA, USA) were used. Immunofluorescence staining was performed as described (Rahman et al., 2005) . Caspase activity was measured using CaspaTag Pan caspase kit (Chemicon, Temecula, LA, USA).
p53-dependent phosphorylation of protein targets R Rahman-Roblick et al treating the cells for 2 h with the transcription-inhibitor actinomycin D (actD) prior to MMC treatment and performed immunoprecipitation as described above. Inhibition of transcription was confirmed by western blot analysis of the p53 targets p21 and MDM2 (Supplementary Figure 6a) . Western blot analysis of ANXA1 after immunoprecipitation with anti-pSTT showed no increased phosphorylation upon transcription inhibition, indicating that phosphorylation of this protein is transcription dependent (data not shown). In contrast, phosphorylation of DJ-1 was unaffected after treatment with actD, suggesting that DJ-1 phosphorylation is a transcription-independent event (Supplementary Figure 6b ). p53 was also phosphorylated in a transcription-independent manner (Supplementary Figure 6c) .
How does p53 regulate phosphorylation of the identified proteins? We found that ANXA1 is phosphorylated in a transcription-dependent manner whereas DJ-1 is phosphorylated independently of transcription. It is conceivable that p53 activates transcription of one or several kinases that phosphorylate a set of target proteins including ANXA1. Thus, this would represent a transcription-dependent secondary effect of p53 activation. Alternatively, p53 could stabilize one or several kinases by transcription-independent mechanisms, for instance via protein-protein interaction. This could be the mechanism behind phosphorylation of DJ-1. We have previously observed that mitogen-activated protein kinase (MAPK) 8, also known as c-Jun N-terminal protein kinase 1 (JNK1), is upregulated by p53 (Rahman-Roblick et al., 2007) . This kinase is activated by various cellular stresses and mediates immediate-early gene expression in response to such stimuli. JNK1 is also important for UV-induced phosphorylation of p53 and p53-mediated apoptosis (Chen et al., 2003; Liu et al., 2004) . It is thus plausible that JNK1 is responsible for p53-dependent phosphorylation of specific proteins, including the proteins identified here. Interestingly, several of identified proteins, including ANXA1, hnRNP-E1 and hnRNP L, contain the minimal phosphorylation consensus sequence for MAPKs, suggesting that they are targets for JNK1-mediated phosphorylation. However, other proteins, for example DJ-1 and Nm23, do not have such consensus sequences, indicating the existence of additional p53-induced kinases or regulators of kinases that can affect phosphorylation of these proteins.
To investigate the possibility that JNK1 is involved in phosphorylation of ANXA1 and even DJ-1, we performed immunoprecipitation with the anti-pSTT antibody following siRNA knockdown of JNK1 in MMC-treated p53 þ / þ cells. As expected, ANXA1 was phosphorylated in the cells treated with siCtrl but not in cells treated with JNK1 siRNA, indicating that phosphorylation of ANXA1 is mediated by JNK1 (Supplementary Figure 7a ). Interestingly, phosphorylation of DJ-1 was also inhibited in these cells, suggesting that JNK1 or a downstream target of JNK1 is involved in DJ-1 phosphorylation (Supplementary Figure 7a) . Downregulation of JNK1 mRNA was confirmed by real-time PCR (Supplementary Figure 7b) .
Phosphorylation is one of the most common modifications that affect protein function. In a recent study, we identified 55 novel p53 targets by a proteomic approach (Rahman-Roblick et al., 2007) . Here, we asked whether activation of p53 results in specific changes in phosphorylation state of proteins using 2DE and mass spectrometry. The availability of Pro-QD staining solution allows detection of phosphate groups attached to tyrosine, serine or threonine residues in 2DE gels. Using this technique we found that activation of p53 by treatment with MMC induces changes not only in total expression levels as detected by SR staining, but also in phosphorylation of a number of proteins (Table 1) . We identified proteins that showed increased or decreased phosphorylation without any changes in total expression levels upon p53 activation, and proteins that showed p53-dependent changes in both total levels and phosphorylation.
ANXA1 belongs to a family of calcium-dependent phospholipid-binding proteins and has anti-inflammatory functions. Overexpression of ANXA1 promotes apoptosis associated with caspase-3 activation (Solito et al., 2001 ). ANXA1 was identified as an 'eat-me' signal on apoptotic cells that are recognized and ingested by phagocytes (Arur et al., 2003) . Thus, ANXA1 is thought to be involved in the anti-inflammatory signaling that allows safe postapoptotic clearance of dead cells. Furthermore, pro-inflammatory stimuli induce serine phosphorylation of ANXA1, which is essential for translocation of ANXA1 from the cytoplasm to the cell membrane and this phosphorylation is dependent on PI3 and MAPKs (Solito et al., 2006) . Therefore, it is conceivable that p53-dependent phosphorylation of ANXA1 is important in regulating the function of the protein. One obvious possibility is that ANXA1 is involved in removal of apoptotic cells upon induction of p53. p53-dependent phosphorylation of protein targets R Rahman-Roblick et al
The Nm23 metastasis inhibition factor was also previously shown by us and others to be upregulated by p53, at both the RNA and protein level (Chen et al., 2003; Rahman-Roblick et al., 2007) . Mutation in the Nm23-H1 gene is associated with metastasis in colorectal cancer (Wang et al., 1993) . Interestingly, in-vivo Nm23 serine phosphorylation levels showed direct correlation with suppression of the tumor metastatic potential of nm23-1-transfected murine melanoma cells, suggesting that phosphorylation of Nm23 is indeed required for its ability to inhibit metastasis (MacDonald et al., 1993) . Our observation that Nm23 is phosphorylated upon p53 induction suggests that p53 may regulate metastasis through posttranslational modifications of this target, in addition to inducing overall expression levels.
DJ-1 is a ubiquitously expressed and highly conserved protein that was originally identified as a mitogendependent oncogene product involved in a Ras-related signal transduction pathway (Nagakubo et al., 1997) . Increased expression has been detected in primary nonsmall cell lung carcinomas and overexpression correlates with negative regulation of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and increased cell survival (Kim et al., 2005) . The function of the DJ-1 protein remains largely elusive but a role in the oxidative stress response has been suggested (Taira et al., 2004) . Furthermore, loss of þ / þ cells after p53 activation. 3D-rendering shows protein spot peak of phosphorylated ANXA1 in the p53 þ / þ cells. (b) Multi-channel viewing was applied for detection of ANXA1 total protein levels by Sypro Ruby (SR) staining (red) as well as phosphorylation status using Pro-QD staining (blue) after MMC treatment. 2D gel electrophoresis was carried out as outlined (Rahman-Roblick et al., 2007) . Phosphoprotein staining of 2DE polyacrylamide gels using the Pro-QD phosphoprotein gel stain was performed according to the manufacturer's protocol (Molecular probes-Invitrogen, Sweden). The SDS gels were de-stained and re-stained with SR staining solution for total protein staining. Scanning and image analysis was performed as described previously. PDQuest (version 8.0.1) was used for semiautomated spot detection and matching. Multichannel viewer function was applied for gel image overlay. Boolean analysis combining Student's t-test and qualitative analysis defined phosphorylated proteins in the HCT116 cells following p53 induction. Po0.5 was considered as statistically significant. Statistical analysis was based on the PDQuest analytical software package. SR-stained protein spots of interest from the 2D gels were excised using EXQuest spot cutter (Bio-Rad). Manual in-gel digestion was performed as described (Rahman-Roblick et al., 2007) . Peptide mass fingerprinting was performed in an Ultraflex TOF/TOF instrument (Bruker Daltonics).
p53-dependent phosphorylation of protein targets R Rahman-Roblick et al DJ-1 leads to neurodegeneration and mutations in the DJ-1 gene are associated with PARK7, a monogenic form of human parkinsonism (Bonifati et al., 2003) . In a recent report, knockdown of DJ-1 in zebrafish model of Parkinson's disease resulted in increased expression of p53 and Bax, suggesting that absence of DJ-1 activates the death pathway (Bretaud et al., 2007) . Our finding that DJ-1 is phosphorylated upon activation of p53 raises the possibility that p53-dependent phosphorylation of DJ-1 inhibits its function and thus facilitates apoptosis.
In summary, we have shown that p53 is able to induce phosphorylation of a number of proteins involved in various cellular activities. Our findings add new insights to the current understanding of p53's capabilities. Additional work is required to elucidate the mechanisms underlying this new role of p53, and determine if p53-dependent phosphorylation can be exploited for novel anticancer therapeutic strategies.
